Healthcare group, Stirling Products Limited (ASX:STI) is pleased to advise:
High Density Aerosol (HDA) License Agreement
The Company and its joint venture partner, Zodiac Capital Limited have entered into a conditional Agreement with a St Petersburg based Cice Group company for the exclusive use of the joint venture's licensed High Density Aerosol (HDA) for the pulmonary delivery of a proprietary form of deltaran. Deltaran has been approved in Russia to treat brain damage, dementia and Alzheimer's disease.
For further information please download PDF below:
